Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report

Journal of Pediatrics

Volumn 153, Issue 2, 2008, Pages

  Farrell, Philip M ^a   Rosenstein, Beryl J ^b   White, Terry B ^d   Accurso, Frank J ^e   Castellani, Carlo ^f   Cutting, Garry R ^c   Durie, Peter R ^g   LeGrys, Vicky A ^h   Massie, John ⁱ   Parad, Richard B ^j   Rock, Michael J ^a   Campbell III, Preston W ^d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d CYSTIC FIBROSIS FOUNDATION   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f Civile Maggiore Hospital   (Italy)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ ROYAL CHILDREN'S HOSPITAL   (Australia)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE; ELASTASE; PANCREAS ENZYME; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; BACTERIUM CULTURE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DNA DETERMINATION; FAMILY HISTORY; GENE DELETION; GENETIC ANALYSIS; GENOTYPE; HUMAN; LABORATORY TEST; LIVER DISEASE; LIVER FUNCTION TEST; LUNG DISEASE; LUNG FUNCTION TEST; LUNG LAVAGE; MEDICAL CARE; MISSENSE MUTATION; NEWBORN SCREENING; OROPHARYNX; OUTCOME ASSESSMENT; PANCREAS DISEASE; PANCREAS FUNCTION; PERINATAL PERIOD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REFERENCE VALUE; SINUSITIS; STOP CODON; SWEAT TEST; THORAX RADIOGRAPHY; UNITED STATES;

ADULT; AGE FACTORS; CHLORIDES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DATA INTERPRETATION, STATISTICAL; DNA MUTATIONAL ANALYSIS; FOUNDATIONS; GENETIC SCREENING; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; SWEAT;

EID: 47049115524     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2008.05.005     Document Type: Article

References (80)

1. Sontag M.K., Hammond K.B., Zielenski J., Wagener J.S., and Accurso F.J. Two-tiered immunoreactive trypsinogen (IRT/IRT)-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. J Pediatr 147 Suppl (2005) S83-S88
2. Parad R.B., and Comeau A.M. Newborn screening for cystic fibrosis. Pediatr Ann 32 (2003) 528-535
3. Comeau A.M., Parad R.B., Dorkin H.L., Dovey M., Gerstle R., Haver K., et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics 113 (2004) 1573-1581
4. Cystic Fibrosis Foundation Patient Registry, 2005 Annual Data Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation.
5. Farrell P.M., Lai H.C., Li Z., Kosorok M.R., Laxova A., Green C.G., et al. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough!. J Pediatr 147 Suppl (2005) S30-S36
6. Dankert-Roelse J.E., and Mérelle M.E. Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe. J Pediatr 147 Suppl (2005) S15-S20
7. Rosenfeld M. Overview of published evidence on outcomes with early diagnosis from large US observational studies. J Pediatr 147 Suppl (2005) S11-S14
8. Accurso F.J., Sontag M.K., and Wagener J.S. Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr 147 Suppl (2005) S37-S41
9. Palomaki G.E., Haddow J.E., Bradley L.A., and FitzSimmons S.C. Updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians. Genet Med 4 (2002) 90-94
10. De Boeck K., Wilschanski M., Castellani C., Taylor C., Cuppens H., Dodge J., et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 61 (2006) 627-635
11. Parad R.B., and Comeau A.M. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm. J Pediatr 147 Suppl (2005) S78-S82
12. Rosenstein B., and Cutting G. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 132 (1998) 589-595
13. Alper O.M., Wong L.J., Young S., Pearl M., Graham S., Sherwin J., et al. Identification of novel and rare mutations in California Hispanic and African-American cystic fibrosis patients. Hum Mutat 24 (2004) 353 corr 2005;25:223
14. Groman J.D., Karczeski B., Sheridan M., Robinson T.E., Fallin M.D., and Cutting G.R. Phenotypic and genetic characterization of patients with features of "nonclassic" forms of cystic fibrosis. J Pediatr 146 (2005) 675-680
15. Mickle J.E., and Cutting G.R. Genotype-phenotype relationships in cystic fibrosis. Med Clin North Am 84 (2000) 597-607
16. Wang X., Moylan B., Leopold D.A., Kim J., Rubenstein R.C., Togias A., et al. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 284 (2000) 1814-1819
17. Feranchak A.P. Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep 6 (2004) 231-239
18. Cipolli M., Castellani C., Wilcken B., Massie J., McKay K., Gruca M., et al. Pancreatic phenotype in cystic fibrosis patients identified by mutation screening. Arch Dis Child 92 (2007) 842-846
19. Comeau A.M., Accurso F.J., White T.B., Campbell III P.W., Hoffman G., Parad R.B., et al. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics 119 (2007) 495-518
20. Centers for Disease Control and Prevention. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. Morb Mortal Recomm Rep 53 RR-13 (2004) 1-36
21. Wilcken B., Wiley V., Sherry G., and Bayliss U. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies. J Pediatr 127 (1995) 965-970
22. Waters D.L., Dorney S.F., Gaskin K.J., Gruca M.A., O'Halloran M., and Wilcken B. Pancreatic function in infants identified as having cystic fibrosis in a neonatal screening program. N Engl J Med 322 (1990) 303-308
23. Farrell P.M., Kosorok M.R., Laxova A., Shen G., Koscik R.E., Bruns W.T., et al. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med 337 (1997) 963-969
24. Gibson L.E., and Cooke R.E. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 23 (1959) 545-549
25. Quinton P.M. Chloride impermeability in cystic fibrosis. Nature 301 (1983) 421-422
26. Legrys V.A., Yankaskas J.R., Quittell L.M., Marshall B.C., and Mogayzel Jr. P.J. Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr 151 (2007) 85-89
27. Clinical Laboratory Standards Institute (formerly National Committee for Clinical Laboratory Standards). Sweat testing: sample collection and quantitative analysis. Approved guideline. Document C34-A2, National Committee for Clinical Laboratory Standards (2000)
28. College of American Pathologists. Chemistry checklist, laboratory accreditation program. Accessed November 6, 2007. http://www.cap.org/apps/docs/laboratory_accreditation/checklists/chemistry_and_toxicology_april2006.pdf
29. Eng W., LeGrys V.A., Schechter M.S., Laughon M.M., and Barker P.M. Sweat-testing in preterm and full-term infants less than 6 weeks of age. Pediatr Pulmonol 40 (2005) 64-67
30. Parad R.B., Comeau A.M., Dorkin H.L., Dovey M., Gerstle R., Martin T., et al. Sweat testing newborn infants detected by cystic fibrosis newborn screening. J Pediatr 147 Suppl (2005) S69-S72
31. Funk M., and LeGrys V.A. Testing diagnostic tests: why size matters. J Pediatr 146 (2005) 159-162
32. Barben J., Ammann R.A., Metlagel A., and Schoeni M.H. Conductivity determined by a new sweat analyzer compared to chloride concentrations for the diagnosis of cystic fibrosis. J Pediatr 146 (2005) 183-188
33. Losty H.C., Wheatly H., and Doull I. The evaluation of a novel conductometric device for the diagnosis of cystic fibrosis. Ann Clin Biochem 43 (2006) 375-381
34. LeGrys V.A. Assessing quality assurance for sweat chloride testing. Clin Lab Sci 5 (1992) 354-357
35. LeGrys V.A. Stability of chloride in sweat testing. Clin Lab Sci 6 (1993) 156-157
36. Shwachman H., and Mahmoodian A. Pilocarpine iontophoresis sweat testing: results of seven years' experience. In: Rossi E., and Stoll E. (Eds). Modern Problems in Pediatrics (1967), Karger, Basel 158-182
37. Mishra A., Greaves R., and Massie J. The limitations of sweat electrolyte reference intervals for the diagnosis of cystic fibrosis: a systematic review. Clin Biochem Rev 28 (2007) 60-76
38. Massie R.J., Olsen M., Glazner J., Robertson C.F., and Francis I. Newborn screening for cystic fibrosis in Victoria: 10 years' experience (1989-1998). Med J Aust 172 (2000) 584-587
39. Massie R.J.H., Gaskin K.J., Van Asperen P.P., Bayliss U., and Wilcken B. The reliability of sweat testing at six weeks following newborn screening for cystic fibrosis in NSW, 1995-1996 [abstract]. Am J Resp Crit Care Med 157 (1998) 126
40. Farrell P.M., and Koscik R.E. Sweat chloride concentrations in infants homozygous or heterozygous for ΔF508 cystic fibrosis. Pediatrics 97 (1996) 524-528
41. Massie J., Gaskin K., Van Asperen P., and Wilcken B. Sweat testing following newborn screening for cystic fibrosis. Pediatr Pulmonol 29 (2000) 452-456
42. Padoan R.A.B., Seia M., and Corbetta C. Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations. Eur J Pediatr 161 (2002) 212-215
43. Massie J., and Clements B. Diagnosis of cystic fibrosis after newborn screening: the Australasian experience. Twenty years and five million babies later: a consensus statement from the Australasian Paediatric Respiratory Group. Pediatr Pulmonol 39 (2005) 440-446
44. Taccetti G., Festini F., Braccini G., Campana S., and deMartino M. Sweat testing in newborns positive to neonatal screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 89 (2004) F463-F464
45. Rock M.J., Hoffman G., Laessig R.H., Kopish G.J., Litsheim T.J., and Farrell P.M. Newborn screening for cystic fibrosis in Wisconsin: nine years experience with routine trypsinogen/DNA testing. J Pediatr 147 Suppl (2005) S73-S77
46. Hall S.K., Stableforth D.E., and Green A. Sweat sodium and chloride concentrations: essential criteria for the diagnosis of cystic fibrosis in adults. Ann Clin Biochem 27 Pt 4 (1990) 318-320
47. Mishra A., Greaves R., and Massie J. Sweat electrolytes: Establishing a reference range in adolescents and adults [abstract]. Aust J Med Sci 27 (2006) 171
48. Rock M., Makholm L., Lai H., and Cheng Y. Distribution of sweat chloride values in patients with cystic fibrosis [abstract]. Pediatr Pulmonol 25 Suppl (2003) 337
49. Highsmith W.E., Burch L.H., Zhou Z., Olsen J.C., Boat T.E., Spock A., et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 331 (1994) 974-980
50. Stewart B., Zabner J., Shuber A., Welsh M.J., and McCray P.B. Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. Am J Respir Crit Care Med 151 (1995) 899-903
51. Lebecque P., Leal T., De Boeck C., Jaspers M., Cuppens H., and Cassiman J.J. Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children. Am J Respir Crit Care Med 165 (2002) 757-761
52. Wilschanski M., Dupuis A., Ellis L., Jarvi K., Zielenski J., Tullis E., et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 174 (2006) 787-794
53. Gilljam M., Ellis L., Corey M., Zielenski J., Durie P., and Tullis D.E. Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood. Chest 126 (2004) 1215-1224
54. Nick J.A., and Rodman D.M. Manifestations of cystic fibrosis diagnosed in adulthood. Curr Opin Pulm Med 11 (2005) 513-518
55. Bishop M.D., Freedman S.D., Zielenski J., Ahmed N., Dupuis A., Martin S., et al. The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. Hum Genet 118 (2005) 372-381
56. Wong L.J., Wang J., Zhang Y.H., Hsu E., Heim R.A., Bowman C.M., et al. Improved detection of CFTR mutations in Southern California Hispanic CF patients. Hum Mutat 18 (2001) 296-307
57. Pignatti P.F., Bombieri C., Marigo C., Benetazzo M., and Luisetti M. Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. Hum Mol Genet 4 (1995) 635-639
58. Miller P.W., Hamosh A., Macek Jr. M., Greenberger P.A., MacLean J., Walden S.M., et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet 59 (1996) 45-51
59. Kiesewetter S., Macek Jr. M., Davis C., Curristin S.M., Chu C.S., Graham C., et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet 5 (1993) 274-278
60. Massie R.J., Poplawski N., Wilcken B., Goldblatt J., Byrnes C., and Robertson C. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. Eur Respir J 17 (2001) 1195-1200
61. Scotet V., Audrezet M.-P., Roussey M., Rault G., Dirou-Prigent, Journel H., et al. Immunoreactive trypsin/DNA newborn screening for cystic fibrosis: should the R117H variant be included in CFTR mutation panels?. Pediatrics 118 (2006) e1523-e1529
62. Chmiel J.F., Drumm M.L., Konstan M.W., Ferkol T.W., and Kercsmar C.M. Pitfalls in the use of genotype analysis as the sole diagnostic criterion for cystic fibrosis. Pediatrics 103 (1999) 823-826
63. O'Sullivan B.P., Zwerdling R.G., Dorkin H.L., Comeau A.M., and Parad R. Early pulmonary manifestation of cystic fibrosis in children with the deltaF508/R117H-7T genotype. Pediatrics 118 (2006) 1260-1265
64. Sokol R.Z. Infertility in men with cystic fibrosis. Curr Opin Pulm Med 7 (2001) 421-426
65. Dörk T., Dworniczak B., Aulehla-Scholz C., Wieczorek D., Böhm I., Mayerova A., et al. Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens. Hum Genet 100 (1997) 365-377
66. Durie P.R. Pathophysiology of the pancreas in cystic fibrosis. Neth J Med 41 (1992) 97-100
67. Kerem E., Reisman J., Corey M., Canny G.J., and Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 326 (1992) 1187-1191
68. Drumm M.L., Konstan M.W., Schluchter M.D., Handler A., Pace R., Zou F., et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 353 (2005) 1443-1453
69. Bronstein M.N., Sokol R.J., Abman S.H., Chatfield B.A., Hammond K.B., Hambridge K.M., et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr 120 (1992) 533-540
70. Daftary A., Acton J., Heubi J., and Amin R. Fecal elastase-1: utility in pancreatic function in cystic fibrosis. J Cyst Fibros 5 (2006) 71-76
71. Kori M., Maayan-Metzger A., Shamir R., Sirota L., and Dinari G. Faecal elastase 1 levels in premature and full-term infants. Arch Dis Child Fetal Neonatal Ed 88 (2003) F106-F108
72. Durie P.R., Forstner G.G., Gaskin K.J., Moore D.J., Cleghorn G.J., Wong S.S., et al. Age-related alterations of immunoreactive pancreatic cationic trypsinogen in sera from cystic fibrosis patients with and without pancreatic insufficiency. Pediatr Res 20 (1986) 209-213
73. Sontag M.K., Corey M., Hokanson J.E., Marshall J.A., Sommer S.S., Zerbe G.O., et al. Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening. J Pediatr 149 (2006) 650-657
74. Knowles M.R., Paradiso A.M., and Boucher R.C. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 6 (1995) 445-455
75. Wilson D.C., Ellis L., Zielenski J., Corey M., Ip W.F., Tsui L.C., et al. Uncertainty in the diagnosis of cystic fibrosis: possible role of in vivo nasal potential difference measurements. J Pediatr 132 (1998) 596-599
76. Standaert T.A., Boitano L., Emerson J., Milgram L.J., Konstan M.W., Hunter J., et al. Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol 37 (2004) 385-392
77. Watson M.S., Cutting G.R., Desnick R.J., Driscoll D.A., Klinger K., Mennuti M., et al. Cystic fibrosis population carrier screening: 2004 revision of the American College of Medical Genetics mutation panel. Genet Med 6 (2004) 387-391
78. Sims E.J., Clark A., McCormick J., Mehta G., Connett G., and Mehta A. Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy. Pediatrics 119 (2007) 19-28
79. Farrell P.M. The meaning of "early" diagnosis in a new era of cystic fibrosis care. Pediatrics 119 (2007) 156-157
80. Kerem E., Corey M., Kerem B.S., Rommens J., Markiewicz D., Levison H., et al. The relation between genotype and phenotype in cystic fibrosis: analysis of the most common mutation (delta F508). N Engl J Med 323 (1990) 1517-1522